Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daratumumab in Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)

Next Previous
Trial Profile

Daratumumab in Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Aciclovir; Allopurinol; Amphotericin B; Aprepitant; Chlorphenamine; Chlorphenamine; Ciprofloxacin; Cotrimoxazole; Cyclophosphamide; Cytarabine; Cytarabine; Daratumumab; Dexamethasone; Diphenhydramine; Fibrinogen; Filgrastim; Folinic acid; Foscarnet; Furosemide; Ganciclovir; Granisetron; Hydrocortisone; Idarubicin; Lenograstim; Lenograstim; Levocarnitine; Levofloxacin; Mercaptopurine; Methotrexate; Methylprednisolone; Micafungin; Montelukast; Ondansetron; Paracetamol; Pegaspargase; Prednisone; Rasburicase; Salbutamol; Vincristine
  • Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms DARATALL-VHR

Most Recent Events

  • 23 Oct 2024 Planned End Date changed from 1 Jan 2029 to 1 Oct 2029.
  • 23 Oct 2024 Planned primary completion date changed from 1 Jan 2029 to 1 Oct 2029.
  • 23 Oct 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top